Africa CDC Applauds First Malaria Treatment for Infants Under 5 Kilogrammes
Table of Contents
Addis Ababa, August 16, 2025 – A new era in malaria treatment for the most vulnerable populations has begun with the approval of the first medication specifically formulated for newborns and infants weighing less than five kilogrammes. The Africa Centres for Disease Control and Prevention (Africa CDC) heralded the milestone as a critical step toward closing a long-standing gap in pediatric care across the continent.
A Critical Need Addressed
For years, healthcare providers have faced a significant challenge in treating malaria in very young infants. Existing medications were often unsuitable, requiring modified dosages that carried risks of overdose and toxicity. This new formulation, dissolvable in breast milk and flavored for palatability, offers a safe and effective alternative.
Pro Tip: Early diagnosis and treatment are crucial for managing malaria in infants. Seek immediate medical attention if you suspect your child has contracted the disease.
Collaborative Effort Drives Innovation
The growth of this life-saving treatment was a collaborative undertaking. Novartis and the Medicines for Malaria Venture (MMV) spearheaded the project under the PAMAfrica consortium. Funding was provided by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency.
Eight African nations – Burkina Faso, Côte d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – played a pivotal role through thier participation in essential clinical trials. Their involvement underscores a growing trend of African leadership in driving health innovation and ensuring equitable access to care.
Regulatory Approval and Rollout
Swiss regulators have already granted approval for the new formulation. Rapid approvals are anticipated in the eight participating African countries through the Swiss agency’s marketing Authorisation for global Health Products procedure. Novartis intends to distribute the treatment on a primarily not-for-profit basis, prioritizing access in malaria-endemic regions where approximately 30 million babies are born annually.
“The approval of this treatment is a major step forward in the fight against malaria,” stated Africa CDC Director General dr. Jean Kaseya. “It ensures that even the smallest and most vulnerable infants now have access to safe and effective treatment.”
Africa CDC’s Ongoing Commitment
The Africa CDC will actively support member states in integrating the new formulation into their national health systems. This support will include updating clinical guidelines, providing training for healthcare workers, strengthening surveillance and research efforts, and ensuring equitable access through initiatives like the African Pooled Procurement mechanism (APPM).
Furthermore, the agency will expedite regulatory approvals through a newly established regulatory reliance mechanism involving eight National Regulatory Authorities in collaboration with the African Medicines Regulatory Harmonization (AMRH/AUDA-NEPAD).
Did You No? …
Malaria remains a leading cause of childhood illness and death in sub-Saharan Africa, disproportionately affecting infants and young children.
Key Milestones & Implementation Details
| Milestone | Date |
|---|---|
| Formulation Development | Ongoing (culminating in 2025) |
| Swiss Regulatory approval | August 2025 |
| African Nation Approvals (Expected) | Late 2025 – Early 2026 |
| Widespread Distribution | 2026 onwards |
Dr. Ngashi Ngongo, Principal Advisor to the Africa CDC director General and head of the Mpox Incident Management Support Team, emphasized the significance of Africa-led collaboration. “The approval of the new malaria treatment demonstrates the impact of Africa-led collaboration in delivering health solutions where they’re needed most,” he said.
Looking Ahead: A Malaria-Free future
The Africa CDC remains steadfast in its commitment to eradicating malaria across the continent. Dr. Kaseya concluded, “By making smart investments, implementing well-targeted policies, and deepening collaboration, we can ensure that all African countries become malaria-free within the coming generation.”
The fight against malaria is a complex one, with the Plasmodium falciparum parasite remaining a significant threat, especially in sub-Saharan Africa [[2]].However, advancements like this new infant formulation offer renewed hope for a healthier future.
What challenges do you foresee in ensuring equitable access to this new treatment across all African nations? How can communities play a role in preventing malaria transmission?
Malaria: A Persistent Global Health Challenge
Malaria, caused by Plasmodium parasites transmitted through infected Anopheles mosquitoes, continues to be a major public health concern globally, particularly in tropical and subtropical regions. According to the World Health institution, an estimated 249 million cases were reported in 2022, resulting in 693,000 deaths [[1]]. Recent funding cuts threaten to reverse decades of progress in malaria control and elimination, highlighting the need for sustained investment and innovative solutions.
Frequently Asked Questions About Malaria Treatment
- What is the primary cause of malaria? Malaria is caused by Plasmodium parasites transmitted through the bites of infected Anopheles mosquitoes.
- Who is most vulnerable to severe malaria? Young children,pregnant women,and individuals with weakened immune systems are at the highest risk.
- How does this new treatment differ from existing options? This formulation is specifically designed for infants under 5kg, offering a safe and effective dosage that avoids the risks associated with modifying adult medications.
- What is the African Pooled Procurement Mechanism (APPM)? The APPM is an initiative to ensure equitable access to essential medicines by negotiating lower prices and streamlining procurement processes.
- What role does the Africa CDC play in malaria control? The Africa CDC supports member states in strengthening their health systems, enhancing disease surveillance, and promoting access to effective treatments.
Disclaimer: This article provides general data about malaria treatment and should not be considered medical advice. Please consult with a qualified healthcare professional for diagnosis and treatment.
We hope this article has provided valuable insights into this groundbreaking advancement in malaria treatment. Share this information with your network to raise awareness and support the fight against this devastating disease. Don’t forget to subscribe to our newsletter for more updates on global health issues!
